Accelerating drug development for Alzheimer's disease through the use of data standards

INTRODUCTION: The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data stan...

Descripción completa

Detalles Bibliográficos
Autores principales: Neville, Jon, Kopko, Steve, Romero, Klaus, Corrigan, Brian, Stafford, Bob, LeRoy, Elizabeth, Broadbent, Steve, Cisneroz, Martin, Wilson, Ethan, Reiman, Eric, Vanderstichele, Hugo, Arnerić, Stephen P., Stephenson, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651436/
https://www.ncbi.nlm.nih.gov/pubmed/29067333
http://dx.doi.org/10.1016/j.trci.2017.03.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651436/
https://www.ncbi.nlm.nih.gov/pubmed/29067333
http://dx.doi.org/10.1016/j.trci.2017.03.006

Ejemplares similares